PainReform (PRFX) Competitors $1.39 -0.10 (-6.71%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. HOOK, IMCC, BCDA, PHXM, ALBT, PCSA, APM, ADXN, ERNA, and DWTXShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include HOOKIPA Pharma (HOOK), IM Cannabis (IMCC), BioCardia (BCDA), PHAXIAM Therapeutics (PHXM), Avalon GloboCare (ALBT), Heatwurx (PCSA), Aptorum Group (APM), Addex Therapeutics (ADXN), Ernexa Therapeutics (ERNA), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors HOOKIPA Pharma IM Cannabis BioCardia PHAXIAM Therapeutics Avalon GloboCare Heatwurx Aptorum Group Addex Therapeutics Ernexa Therapeutics Dogwood Therapeutics PainReform (NASDAQ:PRFX) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership. Which has more risk & volatility, PRFX or HOOK? PainReform has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, HOOKIPA Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Does the media prefer PRFX or HOOK? In the previous week, PainReform had 3 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 3 mentions for PainReform and 0 mentions for HOOKIPA Pharma. PainReform's average media sentiment score of 0.99 beat HOOKIPA Pharma's score of 0.00 indicating that PainReform is being referred to more favorably in the media. Company Overall Sentiment PainReform Positive HOOKIPA Pharma Neutral Do analysts recommend PRFX or HOOK? HOOKIPA Pharma has a consensus target price of $4.50, suggesting a potential upside of 410.78%. Given HOOKIPA Pharma's stronger consensus rating and higher probable upside, analysts clearly believe HOOKIPA Pharma is more favorable than PainReform.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00HOOKIPA Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals and insiders have more ownership in PRFX or HOOK? 37.3% of PainReform shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is PRFX or HOOK more profitable? PainReform has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. PainReform's return on equity of 0.00% beat HOOKIPA Pharma's return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A N/A N/A HOOKIPA Pharma -785.66%-120.09%-77.14% Which has better earnings and valuation, PRFX or HOOK? PainReform has higher earnings, but lower revenue than HOOKIPA Pharma. HOOKIPA Pharma is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$14.59M-$147.33-0.01HOOKIPA Pharma$9.35M1.15-$43.50M-$5.85-0.15 SummaryPainReform beats HOOKIPA Pharma on 8 of the 15 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.80M$2.50B$5.65B$10.29BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-0.0123.2875.8626.14Price / SalesN/A564.82515.95170.63Price / CashN/A174.1537.5661.52Price / Book0.675.1512.886.30Net Income-$14.59M$32.95M$3.29B$271.03M7 Day Performance-2.11%0.15%-0.24%-0.13%1 Month Performance-20.11%5.09%3.87%6.43%1 Year Performance-47.34%1.17%68.39%28.82% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform0.5892 of 5 stars$1.39-6.7%N/A-39.0%$2.80MN/A-0.014Gap DownHOOKHOOKIPA Pharma2.4122 of 5 stars$0.90-3.7%$4.50+402.5%-80.0%$10.92M$9.35M-0.15160IMCCIM Cannabis0.67 of 5 stars$2.07+7.3%N/A-22.3%$10.87M$39.44M-3.83340News CoverageGap UpBCDABioCardia3.4449 of 5 stars$1.87-13.3%$25.00+1,240.5%-38.6%$10.82MN/A-1.0140News CoveragePositive NewsAnalyst ForecastInsider TradeAnalyst RevisionGap DownHigh Trading VolumePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ALBTAvalon GloboCare0.7305 of 5 stars$2.68+3.1%N/A-23.3%$10.29M$1.33M-0.135Gap UpPCSAHeatwurx3.7249 of 5 stars$0.20-0.7%$1.00+402.5%-84.3%$10.02MN/A-0.0920Positive NewsAPMAptorum Group0.9272 of 5 stars$1.87-4.8%N/A-12.8%$9.97MN/A0.0030ADXNAddex Therapeutics2.8617 of 5 stars$9.38-2.5%$30.00+219.8%-8.4%$9.94M$170.62K-27.5930Upcoming EarningsERNAErnexa Therapeutics0.6774 of 5 stars$1.23+4.3%N/A-93.3%$9.44M$580K-0.1510DWTXDogwood Therapeutics2.0029 of 5 stars$4.92+1.0%$10.00+103.3%N/A$9.40MN/A-0.265Positive News Related Companies and Tools Related Companies HOOK Competitors IMCC Competitors BCDA Competitors PHXM Competitors ALBT Competitors PCSA Competitors APM Competitors ADXN Competitors ERNA Competitors DWTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
